Please login to the form below

Not currently logged in
Email:
Password:

Patheon hires Covance's Michael Lehmann for global pharma role

He joins the contract development and manufacturing company as president of global pharmaceutical development services

Michael Lehmann has left contract research organisation Covance to join Patheon as president of global pharmaceutical development services.

Patheon, which provides both contract development and manufacturing services to pharma companies, said that Lehmann's appointment will help drive the company's growth as it continues to transform its business amid varying marketing conditions.

This includes the company's recent acquisition of speciality pharma firm Banner Pharmacaps for $255m.

"I am pleased to be welcoming Mike and getting him quickly integrated with Patheon's leadership team," stated James Mullen, Patheon's CEO.

"He is a highly accomplished senior executive with a proven track record in the healthcare, life sciences and drug development sectors.”

Lehmann's most recent role was corporate senior VP and general manager of the global early development business of the contract research organisation (CRO) Covance.

During his time in this role, he helped Covance secure deals with both Lilly and Sanofi.

Prior to joining Covance, Lehmann spent 17 years at GE Healthcare in several senior roles, including general manager of multivendor services.

2nd November 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics